Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] Samsung SDI (006400) – Shinhan Securities | Profit Turnaround · ESS Margin Support · North America LFP Ramp-up / 2026-07-20 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | ADR Listing · PHLX Inclusion · Valuation Re-rating / 2026-06-01 Research
  • [Research] SK hynix (000660 / SKHY) – Kyobo | HBM4 · Product Mix · LTA / 2026-07-30 Research
  • [Research] Samsung Electro-Mechanics (009150) – Hana Securities | AI Server Demand · Supply Deficit · FCBGA Technical Bottleneck / 2026-07-20 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q4 2025 Earnings Presentation / 2026-01-23 IR Room
  • [IR] Samsung Electronics (005930) – Q1 2025 Earnings Presentation / 2025-04-30 IR Room
  • [Research] SK hynix (000660 / SKHY) – Kiwoom | Commodity Memory Pricing · Server Demand · Earnings Upgrades / 2026-01-30 Research
  • [Research] Samsung SDI (006400/KS) – SK Securities | Prominent Base Effects · Conservative CapEx Management · Compelling Valuation / 2026-02-03 Research

[Research] LIG D&A (079550) – DS Investment & Securities | Order Expansion · Iraq Cheongung-II Mass Production · Long-term Earnings Growth / 2026-08-07

Posted on August 7, 2026August 21, 2026 By ksb220805@gmail.com

Brokerage : DS Investment & Securities

Analyst : Taeho Kang

Investment Rating : BUY (Maintain)

Target Price : KRW 1,250,000 (Maintain)

Core Momentum : Expanding export revenue mix overcoming short-term 2Q seasonality, with medium-to-long term high growth secured by Iraq Cheongung-II mass-production revenue recognition beginning in 2027 and expanding order pipelines across Southeast Asia and Eastern Europe

📊 1. [Valuation & Key Financial Metrics]

  • Investment Rating & Target Price: Rating BUY (Maintain), Target Price KRW 1,250,000 (Maintain), Current Price KRW 702,000 (As of 2026-08-06), Upside Potential 78.1%
  • Target Price Rationale & Order Backlog: Facility investments at Gimcheon and Gumi plants will begin showing full expansion benefits in 2028 to meet rising order demands; 2026 year-end backlog is projected to exceed 2025 year-end levels of KRW 26 Trillion (Order backlog at KRW 24 Trillion as of 2Q26)
  • 2026 Guidance & Earnings Forecast Highlights:
    • Full-year operating margin guidance raised from 7% to 8%
    • 2026 estimated annual revenue of KRW 5.1 Trillion (+19.3% YoY) and operating profit of KRW 434.6 Billion (+36.1% YoY, OPM 8.5%)
    • Projected 2025–2028 operating profit CAGR of 40%
  • Financial Forecasts & Historicals (K-IFRS Consolidated):
    • 2024: Revenue KRW 3,276 Billion, Operating Profit KRW 223 Billion (OP Margin 6.8%), Pre-tax Profit KRW 203 Billion, Controlling Net Profit KRW 219 Billion, EPS KRW 9,974 (YoY +25.4%), ROE 19.4%, PER 22.1x, PBR 4.0x, EV/EBITDA 15.5x
    • 2025: Revenue KRW 4,307 Billion, Operating Profit KRW 319 Billion (OP Margin 7.4%), Pre-tax Profit KRW 278 Billion, Controlling Net Profit KRW 253 Billion, EPS KRW 11,516 (YoY +15.5%), ROE 19.2%, PER 36.6x, PBR 6.5x, EV/EBITDA 22.9x
    • 2026F: Revenue KRW 5,138 Billion, Operating Profit KRW 435 Billion (OP Margin 8.5%), Pre-tax Profit KRW 461 Billion, Controlling Net Profit KRW 373 Billion, EPS KRW 17,072 (YoY +48.2%), ROE 23.6%, PER 41.1x, PBR 8.9x, EV/EBITDA 28.9x
    • 2027F: Revenue KRW 6,187 Billion, Operating Profit KRW 666 Billion (OP Margin 10.8%), Pre-tax Profit KRW 689 Billion, Controlling Net Profit KRW 567 Billion, EPS KRW 25,968 (YoY +52.1%), ROE 28.6%, PER 27.0x, PBR 6.9x, EV/EBITDA 20.2x
    • 2028F: Revenue KRW 7,288 Billion, Operating Profit KRW 866 Billion (OP Margin 11.9%), Pre-tax Profit KRW 891 Billion, Controlling Net Profit KRW 734 Billion, EPS KRW 33,599 (YoY +29.4%), ROE 28.5%, PER 20.9x, PBR 5.3x, EV/EBITDA 15.6x
  • Stock Indicators: KOSPI 6,296.4pt, Market Cap KRW 15,444 Billion, Outstanding Shares 22,000 Thousand shares, Par Value KRW 5,000, Capital Stock KRW 110 Billion, 60-Day Avg Daily Trading Volume 220 Thousand shares, 60-Day Avg Daily Trading Value KRW 179,723 Million, Foreign Ownership 26.6%, 52-Week High/Low KRW 1,118,000 / KRW 360,000, Major Shareholders LIG & 9 affiliated parties (38.2%), National Pension Service & 1 affiliated party (10.3%)

🚀 2. [Market Opportunities & Business Outlook]

  • 2Q26 Earnings Review:
    • Consolidated revenue reached KRW 1.1 Trillion (+17.4% YoY) and operating profit came in at KRW 105.7 Billion (+29.5% YoY, OPM 9.5%), missing consensus estimates (KRW 1.17 Trillion revenue, KRW 111.0 Billion operating profit) by roughly 5%.
    • Earnings miss was driven by normalization of UAE Cheongung deliveries (KRW 99 Billion) following early deliveries in 1Q26, alongside operating losses from Ghost Robotics (KRW 12.2 Billion).
    • However, total export portion expanded by +8%p YoY to 25.4%, and operating margin improved by +0.9%p YoY supported by low-20% export profitability.
  • 2H26 & Medium-to-Long Term Outlook:
    • 2H26 operating profit is projected to expand by +23.1% YoY, backed by approximately KRW 240 Billion in UAE Cheongung-II deliveries and Poniard (Bigung) export growth.
    • Iraq Cheongung-II mass-production revenue recognition beginning in 2027 is expected to drive a 2025–2028 operating profit CAGR of 40%.
  • Order Pipeline & Potential Deals:
    • Active order negotiations underway with multiple customers across Southeast Asia (Philippines, etc.) and Eastern Europe, offering room for higher export backlog contributions (currently 57% of total backlog).
    • High probability of securing additional Middle Eastern Cheongung-II export contracts within the year.

📝 Editor’s Comment (Perspective)

The covering analyst views LIG D&A not as a defense contractor vulnerable to quarterly revenue timing or subsidiary expenses, but as a tier-1 defense exporter entering a multi-year compounding growth cycle driven by global air defense demand and scheduled mass deliveries of its secured Middle East backlog. This perspective places greater emphasis on long-term capacity additions at Gimcheon and Gumi plants and high-margin export deliveries driven by Iraq Cheongung-II mass-production revenue recognition beginning in 2027 than on seasonal quarterly earnings variations.

To verify whether this investment thesis continues to materialize, primary focus should be directed toward the delivery pace of UAE Cheongung-II and Poniard exports in 2H26, the formal signing of new export contracts across the Middle East, Southeast Asia (Philippines), and Eastern Europe, and the execution of Iraq Cheongung-II mass-production recognition beginning in 2027. These operational milestones can be monitored through upcoming quarterly earnings releases, corporate IR disclosures, contract award filings, and periodic financial reports.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Defense

Post navigation

Previous Post: [Research] Alteogen (196170) – Shinhan Securities | Record 3 Out-Licensing Deals in 2026 · Rapid Keytruda SC Rollout · H2 Clinical Pipeline Catalysts / 2026-08-06
Next Post: [Research] LIG D&A (079550) – Yuanta Securities | Cheongung-II Demand Surge · OPM Guidance Upgrade · Middle East Overlap / 2026-08-07

Related Posts

  • [Research] LIG D&A (079550) – Hanwha Investment & Securities | 4Q25 Review · Ghost Robotics Impairment Cleared · Margin Expansion / 2026-02-23 Research
  • [Research] ABL Bio (298380) – DS Investment & Securities | ABL001 Data Readout · ABL111 Phase 3 · Grabody B Expansion / 2026-04-07 Research
  • [Research] Samsung Biologics (207940) – iM Securities | Spin-off Valuation Re-rating · Biosecure Act Inflows · Plant 6 Groundbreaking / 2026-01-09 Research
  • [Research] Samsung Biologics (207940) – Hana Securities | Post-Spinoff Profitability · Record KRW 6.8T Orders · Plant 6 Groundbreaking Visibility / 2026-01-07 Research
  • [Research] Samsung Biologics (207940) – Shinhan Securities | Capacity Expansion · Peptide Entry · Guidance Upgrade / 2026-07-24 Research
  • [Research] Samsung SDI (006400) – iM Securities | ESS Business Pivot · AMPC Benefits · Earnings Visibility / 2026-07-31 Research
  • [Research] LIG D&A (079550) – iM Securities | Export Pipeline · CapEx & Hiring Expansion · Global Air Defense Growth / 2026-08-07 Research
  • [IR] SK hynix (000660 / SKHY) – Q4 2023 Earnings Presentation / 2024-01-25 IR Room
  • [Research] Celltrion (068270) – Shinhan Securities | New Product Sales Expansion · Operating Leverage · Global CMO Contracts / 2026-05-15 Research
  • [Research] Samsung Biologics (207940) – iM Securities | Annual Operating Profit Surpasses KRW 2T · Pure-CDMO Transition · Three-Pillar Growth Strategy / 2026-01-22 Research
  • [Research] Samsung Electro-Mechanics (009150) – IBK Securities | CAPEX Surge · Foreign Inflows · Target Price Upgrade / 2026-07-16 Research
  • [Research] LIG D&A (079550) – Kiwoom Securities | Expanding Order Opportunities · 1Q26 Earnings Beat · Global Air Defense Growth / 2026-05-08 Research
  • [IR] Samsung Electronics (005930) – Q1 2025 Earnings Presentation / 2025-04-30 IR Room
  • [IR] SK hynix (000660 / SKHY) – Q3 2025 Earnings Presentation / 2025-10-29 IR Room

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme